BioSig Increases Case Volume Estimates
November 01 2021 - 12:30PM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it exceeded its procedural target of
1500 patient cases in 2021.As of October 21, 2021, the PURE EP(tm)
System had been used in over 1560 patient cases by 71 physicians,
up from 1000 cases in June 2021, when the procedural guidance was
raised amid increased technology usage in elective procedures. As
the adoption of the technology increases and the COVID-19
hospitalization rates continue to decline, the Company intends to
complete between 1700-1800 procedures by the end of 2021.
“We are seeing increased utilization of PURE EP(tm) in the 13
hospitals we are currently working in. Physicians recognize value
both clinically and economically or they would not be increasing
their usage. Hospitals are rapidly scaling their elective
procedures and thus we are now seeing increased case volumes and
commercial activity,” commented Kenneth L. Londoner, Chairman and
CEO of BioSig Technologies, Inc.
Clinical data acquired by the PURE EP(tm) System in a
multi-center study at Texas Cardiac Arrhythmia Institute at St.
David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts
General Hospital was recently published in the Journal of
Cardiovascular Electrophysiology and is available electronically
with open access via the Wiley Online Library. Study results showed
93% consensus across the blinded reviewers with a 75% overall
improvement in intracardiac signal quality and confidence in
interpreting PURE EP(tm) signals over conventional sources.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording, and
storing electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024